RXCELERATE LIMITED

1. RXCELERATE LIMITED 2013-02-05 → present
2. TCP BIOTECH LIMITED 2012-11-07 → 2013-02-05

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Peters Elworthy & Moore

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors have adopted the going concern basis in preparing these financial statements. In assessing whether the going concern assumption is appropriate, the Directors have taken into account all relevant information about the current status of the Group's operations and its debt obligations. The Directors have a reasonable expectation that both the Group and the Company have adequate resources to meet their liabilities as they fall due and to continue operations for the foreseeable future, being a period of at least 12 months following the approval of these financial statements. This expectation was arrived at following a review of cash resources, cashflow projections, customer order book, and pipeline of future projects. The Directors monitor the cash position of the Group and the Company regularly. Taking account of the current trading position and financing facilities, the Directors consider that the assumptions made are appropriate and are satisfied that the Group and the Company are a going concern.”

Group structure

1. RXCELERATE LIMITED · parent
   1. RxBiologics Limited 80% · England and Wales · Research and development
   2. The Cambridge Partnership Limited 67% · England and Wales · Financial management
   3. Total Scientific Limited 100% · England and Wales · Non-trading
   4. RxCelerate, Inc. 100% · USA · Sales and marketing activities in North America
   5. Methuselah Health UK Limited 100% · England and Wales · Research and development

Significant events

• “2024 was a challenging year for the drug discovery and development sector, with a decline in new financings for biotechnology companies both in the UK (the major market for the Group) and the US, resulting in a decline in revenues. The Group invested in new services including its Galaxy™ antibody discovery platform and RxNfinity™ AI-enabled small molecule platform.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -17%

  £13,943,000 → £11,567,000

• Cash

  -77.7%

  £3,071,000 → £684,000

• Net assets

  -46.7%

  £4,413,000 → £2,354,000

• Employees

  +11.5%

  87 → 97

• Operating profit

  -231.9%

  £1,693,000 → -£2,233,000

• Profit before tax

  -281.2%

  £1,307,000 → -£2,368,000

• Wages

  +17%

  £4,461,000 → £5,220,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers